QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
TSE:EXE

Extendicare (EXE) Stock Price, News & Analysis

C$6.78
+0.04 (+0.59%)
(As of 02/22/2024 ET)
Today's Range
C$6.68
C$6.79
50-Day Range
C$6.74
C$7.36
52-Week Range
C$5.75
C$7.64
Volume
118,175 shs
Average Volume
85,542 shs
Market Capitalization
C$566.20 million
P/E Ratio
32.29
Dividend Yield
7.08%
Price Target
C$7.50

Extendicare MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
10.6% Upside
C$7.50 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
1.18mentions of Extendicare in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.42 out of 5 stars


EXE stock logo

About Extendicare Stock (TSE:EXE)

Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as contract and consulting services to third parties. It operates LTC homes and retirement communities, as well as home health care operations under the Extendicare, ParaMed, Extendicare Assist, and SGP Partner Network brands. The company was incorporated in 1968 and is based in Markham, Canada.

EXE Stock Price History

EXE Stock News Headlines

Extendicare Opens the Market
Top Analyst Exposes Imminent Crisis Hurtling Towards America
The man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…
EXE:CA Extendicare Inc.
Extendicare Announces 2023 Third Quarter Results
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Closing Bell: Extendicare Inc flat on Thursday (EXE)
EXE.TO - Extendicare Inc.
Extendicare Announces Closing of Transaction with Axium
Closing Bell: Extendicare Inc flat on Monday (EXE)
3 Dividend Stocks to Buy for Income
This 6.5% Dividend Stock Pays You Every Month!
See More Headlines
Receive EXE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Extendicare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend
1/30/2024
Dividend Payable
2/15/2024
Today
2/22/2024
Ex-Dividend for 3/15 Dividend
2/28/2024
Next Earnings (Confirmed)
3/07/2024
Dividend Payable
3/15/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Care Facilities
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
23,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$7.50
High Stock Price Target
C$7.50
Low Stock Price Target
C$7.50
Potential Upside/Downside
+10.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
C$17.66 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.27 billion
Cash Flow
C$2.12 per share
Book Value
C$1.14 per share

Miscellaneous

Free Float
N/A
Market Cap
C$566.20 million
Optionable
Not Optionable
Beta
1.22
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Michael R. Guerriere M.D. (Age 60)
    MBA, CEO, President & Director
    Comp: $1.11M
  • Mr. David E. Bacon
    Senior VP & CFO
  • Mr. John Toffoletto
    Senior VP, Chief Legal Officer & Corporate Secretary
  • Dr. Matthew Morgan
    Chief Medical Officer
  • Mr. Steve Paraskevopoulos
    Senior Vice President of ParaMed & CTO
  • Joe Belinsky
    VP of Information Technology & Chief Information Officer
  • Ms. Jillian E. Fountain
    Vice President of Investor Relations
  • Ms. Kathryn Killoran Bradley
    Vice President of Corporate Development
  • Ms. Katie LeMoyne
    Senior VP & Chief HR Officer
  • Ms. Wendy Gilmour
    Senior VP of LTC Operations














EXE Stock Analysis - Frequently Asked Questions

Should I buy or sell Extendicare stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Extendicare in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EXE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EXE, but not buy additional shares or sell existing shares.
View EXE analyst ratings
or view top-rated stocks.

What is Extendicare's stock price target for 2024?

3 brokerages have issued twelve-month target prices for Extendicare's shares. Their EXE share price targets range from C$7.50 to C$7.50. On average, they predict the company's share price to reach C$7.50 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts price targets for EXE
or view top-rated stocks among Wall Street analysts.

How have EXE shares performed in 2024?

Extendicare's stock was trading at C$7.28 at the beginning of 2024. Since then, EXE shares have decreased by 6.9% and is now trading at C$6.78.
View the best growth stocks for 2024 here
.

When is Extendicare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our EXE earnings forecast
.

How often does Extendicare pay dividends? What is the dividend yield for Extendicare?

Extendicare announced a monthly dividend on Thursday, February 15th. Investors of record on Thursday, February 29th will be given a dividend of 0.04 per share on Friday, March 15th. This represents a $0.48 dividend on an annualized basis and a yield of 7.08%. The ex-dividend date is Wednesday, February 28th.
Read our dividend analysis for EXE
.

Is Extendicare a good dividend stock?

Extendicare (TSE:EXE) pays an annual dividend of C$0.48 per share and currently has a dividend yield of 6.93%. EXE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 228.57%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for EXE.

What other stocks do shareholders of Extendicare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Extendicare investors own include Inter Pipeline (IPL), Pembina Pipeline (PPL), BCE (BCE), Chorus Aviation (CHR), Cenovus Energy (CVE), Medical Facilities (DR), Martinrea International (MRE), Air Canada (AC), AltaGas (ALA) and Emera (EMA).

How do I buy shares of Extendicare?

Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:EXE) was last updated on 2/22/2024 by MarketBeat.com Staff